The bioprinting-in-space hype is real, but not for the reason you think. Everyone's fixating on the "wow, organs in orbit" angle—but what actually matters is that microgravity solved a stubborn problem terrestrial bioprinters face: cells clumping and settling during fabrication, which destroys structural integrity. This is legitimate engineering progress, not just a publicity stunt, though the tissue-building timeline is still years away from clinical use. Meanwhile, SUNLU's $56 nylon deal is just commodity filament pricing doing what it always does, and those Prusa firmware increments are maintenance work—neither moves the needle on what's actually changing the 3D printing landscape.